GlassScriptPhysician profile
Amber E Hildebrandt
NPI 1003889643
$608.30
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $608.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $184.61 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $77.17 | 2019 | |
| Pfizer INC. | $59.77 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.54 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.19 | 2019 | |
| Ibsa Pharma INC. | $41.59 | 2019 | |
| Shire North American Group INC | $34.53 | 2019 | |
| Novo Nordisk INC | $29.39 | 2019 | |
| Lilly USA, LLC | $28.54 | 2019 | |
| Glaxosmithkline, LLC. | $22.18 | 2019 | |
| Merck Sharp & Dohme LLC | $16.02 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.77 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Hildebrandt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.